Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96BN8

UPID:
OTUL_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme otulin; OTU domain-containing deubiquitinase with linear linkage specificity; Ubiquitin thioesterase Gumby

ALTERNATIVE UPACC:
Q96BN8; D3DTD3; Q8NAS0; Q96IA3

BACKGROUND:
The protein Ubiquitin thioesterase otulin, known for its specificity in deubiquitinating linear polyubiquitin chains, is integral to angiogenesis, craniofacial and neuronal development, and immune homeostasis. By regulating the canonical Wnt signaling and the activity of the LUBAC complex, otulin plays a critical role in preventing autoimmunity and inflammation.

THERAPEUTIC SIGNIFICANCE:
Given otulin's key role in mitigating autoinflammatory conditions and its association with severe Staphylococcus aureus infections, targeting otulin could offer new avenues for therapeutic intervention. Exploring otulin's mechanisms further could unlock potential strategies for treating related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.